ArticleAsian biomedicine : research, reviews and news2025
Exploring the molecular mechanism of Xiao Ji (
Article in Asian biomedicine : research, reviews and news, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Mechanism Discovery of Acacetin Against Cancers: Insights from Network Pharmacology and Molecular Docking.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In China, Xiao Ji decoction has been used to treat hematuria. However, pharmacological studies on its effects against bladder cancer (BC) remain limited. Objective: This study aims to explore the potential mechanisms of Xiao Ji in treating BC using network pharmacology and molecular docking. Methods: The active constituents of Xiao Ji and their corresponding molecular targets were identified through the utilization of the Traditional Chinese Medicine Systems Pharmacology Database. Genes associated with BC were screened by employing resources including the Online Mendelian Inheritance in Man (OMIM) and GeneCards databases. Furthermore, protein-protein interaction (PPI) networks and networks illustrating the connections between ingredients and their ingredient-target (I-T) were established. The related genes underwent gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Ultimately, molecular docking experiments were conducted to substantiate and reinforce the proposed hypotheses. Results: Four compounds were identified, along with 82 target genes that exhibited associations with BC. In the I-T network, quercetin exhibited the highest degree of association with multiple targets. Within the PPI network, interleukin (IL)IL-6, hypoxia inducible factor 1 subunit alpha (HIF1A), epidermal growth factor receptor (EGFR), and myelocytomatosis oncogene (MYC) were discerned as pivotal genes. The enrichment analysis of the critical genes led to the identification of 92 GO terms and 105 pathways. Furthermore, the results of molecular docking analyses revealed that the active compounds, including acacetin, sitosterol, and stigmasterol, exhibited strong binding affinities with IL-6, EGFR, and MYC. Conclusions: Xiao Ji acts on BC through multiple targets and pathways. This study elucidates the potential mechanisms of Xiao Ji in treating BC, providing new options for BC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.